Michel C. Nussenzweig

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors.

Differential regulation of self-reactivity discriminates between IgG+ human circulating memory B cells and bone marrow plasma cells.

Translocation capture sequencing: a method for high throughput mapping of chromosomal rearrangements.

Polyreactive antibodies in adaptive immune responses to viruses.

Enhanced HIV-1 neutralization by antibody heteroligation.

Activation-induced cytidine deaminase in antibody diversification and chromosome translocation.

Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.

Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state.

The hSSB1 orthologue Obfc2b is essential for skeletogenesis but dispensable for the DNA damage response in vivo.

Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase.

DEC-205 is a cell surface receptor for CpG oligonucleotides.

The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry.

A mouse model for HIV-1 entry.

A Blueprint for HIV Vaccine Discovery.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies.

Mechanism of DNA resection during intrachromosomal recombination and immunoglobulin class switching.

RPA accumulation during class switch recombination represents 5'-3' DNA-end resection during the S-G2/M phase of the cell cycle.

Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching.

Role of 53BP1 oligomerization in regulating double-strand break repair.

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection.

Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

High-throughput sequencing reveals principles of adeno-associated virus serotype 2 integration.

Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model.

Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues.

Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains.

Fate mapping for activation-induced cytidine deaminase (AID) marks non-lymphoid cells during mouse development.

T follicular helper cell dynamics in germinal centers.

Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens.

The origin of B cell recurrent chromosomal translocations: proximity versus DNA damage.

Antibodies in HIV-1 vaccine development and therapy.

Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.).

Intestinal monocytes and macrophages are required for T cell polarization in response to Citrobacter rodentium.

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice.

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia.

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission.

L-Myc expression by dendritic cells is required for optimal T-cell priming.

Structural insights on the role of antibodies in HIV-1 vaccine and therapy.

Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike.

Clonal selection in the germinal centre by regulated proliferation and hypermutation.

Antigen delivery to CD11c+CD8- dendritic cells induces protective immune responses against experimental melanoma in mice in vivo.

Identification of chromosomal translocation hotspots via scan statistics.

Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Classical Flt3L-dependent dendritic cells control immunity to protein vaccine.

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Dynamic signaling by T follicular helper cells during germinal center B cell selection.

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

An inherited immunoglobulin class-switch recombination deficiency associated with a defect in the INO80 chromatin remodeling complex.

A robust pipeline for rapid production of versatile nanobody repertoires.

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants.

Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability.

B cell super-enhancers and regulatory clusters recruit AID tumorigenic activity.

Epigenetic targeting of activation-induced cytidine deaminase.

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.

HIV-1 integration landscape during latent and active infection.

Intra-spike crosslinking overcomes antibody evasion by HIV-1.

Amplification of highly mutated human Ig lambda light chains from an HIV-1 infected patient.

Circulating precursors of human CD1c+ and CD141+ dendritic cells.

Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Clonal analysis of human dendritic cell progenitor using a stromal cell culture.

Immunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice.

HUMORAL IMMUNITY. T cell help controls the speed of the cell cycle in germinal center B cells.

Plasmodium Infection Promotes Genomic Instability and AID-Dependent B Cell Lymphoma.

Defining human dendritic cell progenitors by multiparametric flow cytometry.

Orientation-specific joining of AID-initiated DNA breaks promotes antibody class switching.

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

A New Way to Diversify Antibodies by DNA Transposition.

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.

Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory.

Structural basis for germline antibody recognition of HIV-1 immunogens.

Absence of MHC class II on cDCs results in microbial-dependent intestinal inflammation.

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.

Inducible targeting of cDCs and their subsets in vivo.

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges.

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo.

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption.

Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.

Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site.

HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.

Sequencing and cloning of antigen-specific antibodies from mouse memory B cells.

Human dendritic cells (DCs) are derived from distinct circulating precursors that are precommitted to become CD1c+ or CD141+ DCs.

Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

The cell cycle restricts activation-induced cytidine deaminase activity to early G1.

The Heterogeneity of Ly6C(hi) Monocytes Controls Their Differentiation into iNOS(+) Macrophages or Monocyte-Derived Dendritic Cells.

Progress toward active or passive HIV-1 vaccination.

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals.

RAG1/2 induces genomic insertions by mobilizing DNA into RAG1/2-independent breaks.

Early antibody therapy can induce long-lasting immunity to SHIV.

HIV: Persistence through division.

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.

Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo.

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

The microanatomic segregation of selection by apoptosis in the germinal center.

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.

Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope.

Redemption for self-reactive antibodies.

Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity.

Clonal CD4 T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation.

Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117.

Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency.

Combination therapy with anti-HIV-1 antibodies maintains viral suppression.

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.

The Chromatin Reader ZMYND8 Regulates Igh Enhancers to Promote Immunoglobulin Class Switch Recombination.

Partially Open HIV-1 Envelope Structures Exhibit Conformational Changes Relevant for Coreceptor Binding and Fusion.

A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Relationship between intact HIV-1 proviruses in circulating CD4 T cells and rebound viruses emerging during treatment interruption.

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.

Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic.

HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells.

Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope.

Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques.

Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses.

Protein Amounts of the MYC Transcription Factor Determine Germinal Center B Cell Division Capacity.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.

Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir.

Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study.

Risk of Zika microcephaly correlates with features of maternal antibodies.

Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin.

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity.

A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques.

Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir.

Structural basis for Zika envelope domain III recognition by a germline version of a recurrent neutralizing antibody.

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals.

Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies.

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies.

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses.

Characterization of Co-Formulated High-Concentration Broadly Neutralizing Anti-HIV-1 Monoclonal Antibodies for Subcutaneous Administration.

Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.

Recommendations for measuring HIV reservoir size in cure-directed clinical trials.

Enhanced SARS-CoV-2 Neutralization by Secretory IgA in vitro.

An apoptosis-dependent checkpoint for autoimmunity in memory B and plasma cells.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens.

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection .

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.

A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch.

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.

Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates.

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.

Enhanced SARS-CoV-2 neutralization by dimeric IgA.

Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates.

Persistent Cellular Immunity to SARS-CoV-2 Infection.

Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA.

Single-Cell Sorting of HBsAg-Binding Memory B Cells from Human Peripheral Blood Mononuclear Cells and Antibody Cloning.

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.

Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption.

Evolution of antibody immunity to SARS-CoV-2.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.

Persistent cellular immunity to SARS-CoV-2 infection.

Dynamic regulation of T selection during the germinal centre reaction.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls.

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies.

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies.

Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.

Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B cells.

Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease.

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.

Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus.

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.

Germinal center-dependent and -independent memory B cells produced throughout the immune response.

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.

Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice.

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.

Publisher Correction: Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.

Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York.

Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths.

High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination.

Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence.

Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope.

Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.

Plasma neutralization properties of the SARS-CoV-2 Omicron variant.

Longitudinal clonal dynamics of HIV-1 latent reservoirs measured by combination quadruplex polymerase chain reaction and sequencing.

Germinal Centers.

Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins.

Neutralizing antibodies induced in immunized macaques recognize the CD4-binding site on an occluded-open HIV-1 envelope trimer.

The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.

Prolonged viral suppression with anti-HIV-1 antibody therapy.

Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost.

Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins.

Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial.

Combination anti-HIV antibodies provide sustained virological suppression.

Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans.

Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants.

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection.

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation.

Antibody feedback regulation of memory B cell development in SARS-CoV-2 mRNA vaccination.

Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens.

Two complementary features of humoral immune memory confer protection against the same or variant antigens.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain.

Distinct gene expression by expanded clones of quiescent memory CD4 T cells harboring intact latent HIV-1 proviruses.

Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans.

HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design.

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial.

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8 T cell immunity.

HIV-1 Vpu restricts Fc-mediated effector functions in vivo.

Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination.

Continuous germinal center invasion contributes to the diversity of the immune response.

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape.